The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. Published first on TheFly ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

The Barron’s Hall of Fame advisor recently merged her 38-year Ameriprise practice into Rise Private Wealth Management.